Ionis Pharmaceuticals, Inc. Cash and Restricted Cash
Ionis Pharmaceuticals, Inc. (IONS) had Cash and Restricted Cash of $350.06 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-07-29
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $350.06M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $173.38M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $372.26M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $338.34M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $350.06M 10-Q · filed 2026-07-29 |
| 2026-03-31 | $173.38M 10-Q · filed 2026-04-29 |
| 2025-12-31 | $372.26M 10-Q · filed 2026-07-29 |
| 2025-09-30 | $338.34M 10-Q · filed 2025-10-29 |
| 2025-06-30 | $297.30M 10-Q · filed 2026-07-29 |
| 2025-03-31 | $264.19M 10-Q · filed 2026-04-29 |
| 2024-12-31 | $242.08M 10-Q · filed 2026-07-29 |
| 2024-09-30 | $334.61M 10-Q · filed 2025-10-29 |
| 2024-06-30 | $293.99M 10-Q · filed 2025-07-30 |
| 2024-03-31 | $348.89M 10-Q · filed 2025-04-30 |
| 2023-12-31 | $399.27M 10-K · filed 2026-02-26 |
| 2023-09-30 | $352.06M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $424.79M 10-Q · filed 2024-08-01 |
| 2023-03-31 | $309.03M 10-Q · filed 2024-05-07 |
| 2022-12-31 | $276.47M 10-K · filed 2026-02-26 |
| 2022-09-30 | $314.99M 10-Q · filed 2023-11-02 |
| 2022-06-30 | $521.92M 10-Q · filed 2023-08-09 |
| 2022-03-31 | $542.51M 10-Q · filed 2023-05-03 |
| 2021-12-31 | $869.19M 10-K · filed 2025-02-19 |
| 2021-09-30 | $632.95M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $565.12M 10-Q · filed 2022-08-09 |
| 2021-03-31 | $414.15M 10-Q · filed 2022-05-04 |
| 2020-12-31 | $397.66M 10-K · filed 2024-02-21 |
| 2020-09-30 | $633.06M 10-Q · filed 2021-11-03 |
| 2020-06-30 | $530.18M 10-Q · filed 2021-08-04 |
| 2020-03-31 | $486.19M 10-Q · filed 2021-05-05 |
| 2019-12-31 | $683.29M 10-K · filed 2023-02-22 |
| 2019-09-30 | $247.94M 10-Q · filed 2020-11-04 |
| 2019-06-30 | $272.52M 10-Q · filed 2020-08-05 |
| 2019-03-31 | $375.81M 10-Q · filed 2020-05-06 |
| 2018-12-31 | $278.82M 10-K · filed 2022-02-25 |
| 2018-09-30 | $479.89M 10-Q · filed 2019-11-06 |
| 2018-06-30 | $805.49M 10-Q · filed 2019-08-08 |
| 2018-03-31 | $227.50M 10-Q · filed 2019-05-09 |
| 2017-12-31 | $129.63M 10-K · filed 2021-02-24 |
| 2016-12-31 | $84.69M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |